Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "diabetes"

553 News Found

Zydus receives USFDA approval to market Silodosin and Pregabalin capsules
Drug Approval | December 12, 2022

Zydus receives USFDA approval to market Silodosin and Pregabalin capsules

Silodosin capsules treat signs and symptoms of an enlarged prostate gland


Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business
News | November 30, 2022

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan


AstraZeneca’s Dapagliflozin receives CDSCO approval
Drug Approval | November 30, 2022

AstraZeneca’s Dapagliflozin receives CDSCO approval

Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD


Biocon enters commercialization agreement with Zentiva
News | November 24, 2022

Biocon enters commercialization agreement with Zentiva

Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe


Sonowal inaugurates Regional Research Institute of Unani Medicine in Silchar
News | November 21, 2022

Sonowal inaugurates Regional Research Institute of Unani Medicine in Silchar

The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine


Lupin Q2 FY2023 revenue remains flat
News | November 10, 2022

Lupin Q2 FY2023 revenue remains flat

Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.


IOLCP receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe
News | November 07, 2022

IOLCP receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe

Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion


EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression
Clinical Trials | November 07, 2022

EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression

Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems


Biocon Biologics insulins facility in Malaysia receives EU GMP Certification
News | October 26, 2022

Biocon Biologics insulins facility in Malaysia receives EU GMP Certification

The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.